[Treatment of ocular toxoplasmosis. Part 2: Therapeutic approaches].
Retinochorioditis is the most common complication of ocular toxoplasmosis and also the most dangerous one in respect of central visual acuity. New treatment concepts are increasingly replacing the therapy that had become established since the fifties and that had been based on pyrimethamine and sulphadiazine. The new concepts entail fewer complications and are better accepted by the patients. However, prospective randomised studies that are based on severe criteria could not prove for any of the employed treatment courses that it promotes healing of retinochorioditis or prevents relapses. However, if central visual acuity is endangered, drug therapy should nevertheless be initiated. In babies and in persons with immunodeficiency treatment must be in accordance with the overall pattern of symptoms.